CD38 Monoclonal Antibody Therapies for Multiple Myeloma

摘要: The goal of this review is to provide historical, recent preclinical, and current clinical summaries efforts understand the CD38 molecule develop monoclonal antibodies that target it. We focus particularly on involving multiple myeloma, a malignancy terminally differentiated B cells remains incurable despite many advances. An era anti-CD38 antibody therapy for myeloma approaching, one that, we hope, will enable patients live longer better lives.